Mediwound Ltd.
A biopharmaceutical company that makes NexoBrid, a pineapple-enzyme gel that dissolves dead tissue from severe burn wounds without surgery. Founded in 2000 as a spinoff from Hebrew University of Jerusalem research into bromelain, the enzyme found in pineapple stems. The company's name plays on "medi" (medical) and "wound," reflecting its focus on wound care.
Bought 150
Bought 6.0K
Bought 3.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rubinstein SamuelDirector · 1 transaction | — | 4.3K | — | 150 | — |
| Shamir NachumDirector · 2 transactions | — | 1.2K | — | 6.0K | — |
| Fox David MortonDirector · 3 transactions | — | 750 | — | 3.5K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +9.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.